← All Signals

🏥 FDA: Radnostix — Class III

healthcareneutralSource: FDA
70%Confidence
0Views
FDASource
2026-04-09Date

Summary

Radnostix's Class III recall for a Sodium Iodide I-131 kit component due to specification failures poses lower health risks but highlights quality issues in nuclear medicine supplies. This could disrupt diagnostic imaging procedures and erode trust in specialized medical kits, though the impact is limited to niche applications.

Actionable: Assess the availability of alternative nuclear medicine kits to mitigate potential shortages.

AI Confidence: 70%

Data Points

firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now